Vor Biopharma (VOR) Cash from Investing Activities (2020 - 2026)
Vor Biopharma (VOR) posted quarterly Cash from Investing Activities of -$263.2 million for Q1 2026, down 114350.87% year-over-year from N/an in Q1 2025, and down 437.5% quarter-over-quarter from -$49.0 million in Q4 2025.
Powered by 
Analysis
Vor Biopharma (VOR) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Vor Biopharma (VOR) has reported Cash from Investing Activities for 7 consecutive years, with -$263.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 114350.87% year-over-year to -$263.2 million; the TTM figure through Mar 2026 stood at -$311.8 million (down 692.18% YoY), while the FY2025 annual figure was -$48.8 million, down 150.39% from the prior year.
- Cash from Investing Activities fell to -$263.2 million in Q1 2026 per VOR's latest filing, from -$49.0 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $53.0 million in Q2 2024 and bottomed at -$263.2 million in Q1 2026.
- Historically, Cash from Investing Activities has averaged -$14.0 million across 5 years, with a median of -$34000.0 in 2024.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities surged 604.77% — and 2026, when it slumped 114350.87%.
- Vor Biopharma's Cash from Investing Activities stood at -$97.0 million in 2022, then jumped by 110.65% to $10.3 million in 2023, then sank by 100.7% to -$72000.0 in 2024, then sank by 67919.44% to -$49.0 million in 2025, then tumbled by 437.5% to -$263.2 million in 2026.
- Business Quant data shows VOR's Cash from Investing Activities at -$263.2 million in Q1 2026, -$49.0 million in Q4 2025, and -$244000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Vor Biopharma | 1.36 Bn | 1.36 Bn | - | -36.53 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -36.53 Mn |
| Mar 31, 2026 | -263.24 Mn |
| Dec 31, 2025 | -48.97 Mn |
| Sep 30, 2025 | -244,000.00 |
| Jun 30, 2025 | 646,000.00 |
| Mar 31, 2025 | -230,000.00 |
| Dec 31, 2024 | -72,000.00 |
| Sep 30, 2024 | -34,000.00 |
| Jun 30, 2024 | 52.99 Mn |
| Mar 31, 2024 | 43.97 Mn |
| Dec 31, 2023 | 10.34 Mn |
| Sep 30, 2023 | 40.54 Mn |
| Jun 30, 2023 | 13.64 Mn |
| Mar 31, 2023 | 6.50 Mn |
| Dec 31, 2022 | -97.04 Mn |
| Sep 30, 2022 | 12.70 Mn |
| Jun 30, 2022 | -2.70 Mn |
| Mar 31, 2022 | -7.06 Mn |
| Dec 31, 2021 | -5.95 Mn |
| Sep 30, 2021 | -8.49 Mn |